302 related articles for article (PubMed ID: 29540770)
21. MAPK kinase 3 specifically regulates Fc epsilonRI-mediated IL-4 production by mast cells.
MacNeil AJ; Yang YJ; Lin TJ
J Immunol; 2011 Sep; 187(6):3374-82. PubMed ID: 21841136
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic Strategies for Targeting IL-33/ST2 Signalling for the Treatment of Inflammatory Diseases.
Chen WY; Tsai TH; Yang JL; Li LC
Cell Physiol Biochem; 2018; 49(1):349-358. PubMed ID: 30138941
[TBL] [Abstract][Full Text] [Related]
23. Protein tyrosine phosphatase epsilon is a negative regulator of FcepsilonRI-mediated mast cell responses.
Akimoto M; Mishra K; Lim KT; Tani N; Hisanaga SI; Katagiri T; Elson A; Mizuno K; Yakura H
Scand J Immunol; 2009 May; 69(5):401-11. PubMed ID: 19508371
[TBL] [Abstract][Full Text] [Related]
24. IL-33 causes selective mast cell tolerance to bacterial cell wall products by inducing IRAK1 degradation.
Sandig H; Jobbings CE; Roldan NG; Whittingham-Dowd JK; Orinska Z; Takeuchi O; Akira S; Bulfone-Paus S
Eur J Immunol; 2013 Apr; 43(4):979-88. PubMed ID: 23404570
[TBL] [Abstract][Full Text] [Related]
25. Immunomodulation via novel use of TLR4 by the filarial nematode phosphorylcholine-containing secreted product, ES-62.
Goodridge HS; Marshall FA; Else KJ; Houston KM; Egan C; Al-Riyami L; Liew FY; Harnett W; Harnett MM
J Immunol; 2005 Jan; 174(1):284-93. PubMed ID: 15611251
[TBL] [Abstract][Full Text] [Related]
26. The ST2 pathway is involved in acute pancreatitis: a translational study in humans and mice.
Ouziel R; Gustot T; Moreno C; Arvanitakis M; Degré D; Trépo E; Quertinmont E; Vercruysse V; Demetter P; Le Moine O; McKenzie AN; Delhaye M; Devière J; Lemmers A
Am J Pathol; 2012 Jun; 180(6):2330-9. PubMed ID: 22542450
[TBL] [Abstract][Full Text] [Related]
27. The effects of D3R on TLR4 signaling involved in the regulation of METH-mediated mast cells activation.
Xue L; Geng Y; Li M; Jin YF; Ren HX; Li X; Wu F; Wang B; Cheng WY; Chen T; Chen YJ
Int Immunopharmacol; 2016 Jul; 36():187-198. PubMed ID: 27156126
[TBL] [Abstract][Full Text] [Related]
28. The IL-33/ST2 axis is crucial in type 2 airway responses induced by Staphylococcus aureus-derived serine protease-like protein D.
Teufelberger AR; Nordengrün M; Braun H; Maes T; De Grove K; Holtappels G; O'Brien C; Provoost S; Hammad H; Gonçalves A; Beyaert R; Declercq W; Vandenabeele P; Krysko DV; Bröker BM; Bachert C; Krysko O
J Allergy Clin Immunol; 2018 Feb; 141(2):549-559.e7. PubMed ID: 28532656
[TBL] [Abstract][Full Text] [Related]
29. Mast cells control lung type 2 inflammation via prostaglandin E
Alhallak K; Nagai J; Zaleski K; Marshall S; Salloum T; Derakhshan T; Hayashi H; Feng C; Kratchmarov R; Lai J; Kuchibhotla V; Nishida A; Balestrieri B; Laidlaw T; Dwyer DF; Boyce JA
Immunity; 2024 Jun; 57(6):1274-1288.e6. PubMed ID: 38821053
[TBL] [Abstract][Full Text] [Related]
30. IL-33/ST2 Axis in Organ Fibrosis.
Kotsiou OS; Gourgoulianis KI; Zarogiannis SG
Front Immunol; 2018; 9():2432. PubMed ID: 30405626
[TBL] [Abstract][Full Text] [Related]
31. Berberine suppresses IL-33-induced inflammatory responses in mast cells by inactivating NF-κB and p38 signaling.
Li W; Yin N; Tao W; Wang Q; Fan H; Wang Z
Int Immunopharmacol; 2019 Jan; 66():82-90. PubMed ID: 30445310
[TBL] [Abstract][Full Text] [Related]
32. Activation of LXRs using the synthetic agonist GW3965 represses the production of pro-inflammatory cytokines by murine mast cells.
Nunomura S; Okayama Y; Matsumoto K; Hashimoto N; Endo-Umeda K; Terui T; Makishima M; Ra C
Allergol Int; 2015 Sep; 64 Suppl():S11-7. PubMed ID: 26344074
[TBL] [Abstract][Full Text] [Related]
33. Raf kinase inhibitor protein negatively regulates FcεRI-mediated mast cell activation and allergic response.
Lin W; Su F; Gautam R; Wang N; Zhang Y; Wang X
Proc Natl Acad Sci U S A; 2018 Oct; 115(42):E9859-E9868. PubMed ID: 30282734
[TBL] [Abstract][Full Text] [Related]
34. Beyond IgE: Alternative Mast Cell Activation Across Different Disease States.
Lyons DO; Pullen NA
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098318
[TBL] [Abstract][Full Text] [Related]
35. An ST2-dependent role of bone marrow-derived group 2 innate lymphoid cells in pulmonary fibrosis.
Zhao Y; De Los Santos FG; Wu Z; Liu T; Phan SH
J Pathol; 2018 Aug; 245(4):399-409. PubMed ID: 29722022
[TBL] [Abstract][Full Text] [Related]
36. FcepsilonRI-alpha siRNA inhibits the antigen-induced activation of mast cells.
Safaralizadeh R; Soheili ZS; Deezagi A; Pourpak Z; Samiei S; Moin M
Iran J Allergy Asthma Immunol; 2009 Dec; 8(4):177-83. PubMed ID: 20404387
[TBL] [Abstract][Full Text] [Related]
37. Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33.
Bandara G; Beaven MA; Olivera A; Gilfillan AM; Metcalfe DD
Eur J Immunol; 2015 Nov; 45(11):3034-44. PubMed ID: 26256265
[TBL] [Abstract][Full Text] [Related]
38. Mast cells are essential intermediaries in regulating IL-33/ST2 signaling for an immune network favorable to mucosal healing in experimentally inflamed colons.
He Z; Song J; Hua J; Yang M; Ma Y; Yu T; Feng J; Liu B; Wang X; Li Y; Li J
Cell Death Dis; 2018 Dec; 9(12):1173. PubMed ID: 30518915
[TBL] [Abstract][Full Text] [Related]
39. Early divergence of Fc epsilon receptor I signals for receptor up-regulation and internalization from degranulation, cytokine production, and survival.
Kitaura J; Xiao W; Maeda-Yamamoto M; Kawakami Y; Lowell CA; Kawakami T
J Immunol; 2004 Oct; 173(7):4317-23. PubMed ID: 15383560
[TBL] [Abstract][Full Text] [Related]
40. Effects of IL-33/ST2 pathway in acute inflammation on tissue damage, antioxidative parameters, magnesium concentration and cytokines profile.
Stankovic MS; Janjetovic K; Velimirovic M; Milenkovic M; Stojkovic T; Puskas N; Zaletel I; De Luka SR; Jankovic S; Stefanovic S; Japundzic-Zigon N; Petronijevic ND; Trajkovic V; Trbovich AM
Exp Mol Pathol; 2016 Aug; 101(1):31-7. PubMed ID: 27222019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
